Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

December 11, 2022

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

December 5, 2022

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022

November 21, 2022

Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 14, 2022

Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results

November 3, 2022

Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition

October 4, 2022

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer

September 19, 2022

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

September 1, 2022

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences

August 10, 2022

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 2, 2022

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2023. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations